Summary & Overview
HCPCS J9041: Injection, bortezomib 0.1 mg
HCPCS Level II code J9041 designates administration of bortezomib measured in 0.1 mg increments. Bortezomib is an antineoplastic agent commonly used in hematologic oncology; accurate coding of its dosage is important for clinical documentation, drug utilization tracking, and national billing consistency. This code matters nationally as oncology drug spending and reimbursement remain major components of cancer care financing and influence access to therapy.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of coding and clinical context for J9041, benchmarks for typical use and billing practice (where available), and notes on payer coverage patterns and policy considerations relevant to chemotherapy drug administration. The publication summarizes how J9041 maps to service lines and sites of care, common modifiers applied in practice (full list provided separately), and implications for claim processing and documentation.
This analysis provides a practical reference for billing staff, practice managers, and policy analysts seeking a national overview of code usage, payer handling, and clinical context for bortezomib dosing reported with HCPCS Level II code J9041.
Billing Code Overview
HCPCS Level II code J9041 represents an injection of bortezomib, 0.1 mg. This code is used to report administration of the chemotherapy agent bortezomib in measured 0.1 mg units.
Service type: Drug administration (chemotherapy/antineoplastic agent)
Typical site of service: Outpatient infusion center, hospital outpatient department, or clinic setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with relapsed multiple myeloma presents to the outpatient oncology infusion center for administration of chemotherapy. The regimen includes bortezomib given by subcutaneous or intravenous injection using HCPCS Level II code J9041 billed per 0.1 mg unit. The clinical workflow begins with verification of diagnosis and treatment plan by the oncologist, review of prior therapy and laboratory results (including complete blood count and hepatic function), informed consent, and site-of-care assessment. Nursing performs medication preparation per pharmacy protocol, verifies dose calculation (mg and total mg based on body surface area or flat dosing per regimen), confirms route (subcutaneous preferred for reduced neuropathy risk) and administers the injection. Vital signs and toxicity monitoring occur during and after administration; documentation includes exact dose, lot numbers, route, site, time, and any immediate reaction. Pharmacy and billing convert administered milligrams to units of J9041 (0.1 mg per unit) for accurate HCPCS billing and attach applicable modifier codes to reflect circumstances such as professional services, drug wastage, or patient status changes.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |